Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Corticosteroid Market

ID: MRFR/HC/40337-HCR
200 Pages
Satyendra Maurya
Last Updated: April 15, 2026

Corticosteroid Market Research Report: Size, Share, Trend Analysis By Applications (Allergic Rhinitis, Asthma, Dermatological Disorders, Autoimmune Disorders, Inflammatory Bowel Disease), By Formulation (Tablets, Inhalation, Topical, Injectable, Intranasal), By Route of Administration (Oral, Inhalation, Topical, Injectable), By Therapeutic Area (Respiratory Disorders, Dermatology, Gastroenterology, Rheumatology) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Corticosteroid Market Infographic
Purchase Options
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Application (USD Billion) | |
      1. 4.1.1 Allergic Rhinitis | |
      2. 4.1.2 Asthma | |
      3. 4.1.3 Dermatological Disorders | |
      4. 4.1.4 Autoimmune Disorders | |
      5. 4.1.5 Inflammatory Bowel Disease |
    2. 4.2 Healthcare, BY Formulation (USD Billion) | |
      1. 4.2.1 Tablets | |
      2. 4.2.2 Inhalation | |
      3. 4.2.3 Topical | |
      4. 4.2.4 Injectable | |
      5. 4.2.5 Intranasal |
    3. 4.3 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.3.1 Oral | |
      2. 4.3.2 Inhalation | |
      3. 4.3.3 Topical | |
      4. 4.3.4 Injectable |
    4. 4.4 Healthcare, BY Therapeutic Area (USD Billion) | |
      1. 4.4.1 Respiratory Disorders | |
      2. 4.4.2 Dermatology | |
      3. 4.4.3 Gastroenterology | |
      4. 4.4.4 Rheumatology |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 Pfizer (US) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Merck & Co (US) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 Bristol-Myers Squibb (US) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 GlaxoSmithKline (GB) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Sanofi (FR) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 AstraZeneca (GB) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Novartis (CH) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Mylan (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY APPLICATION |
    7. 6.4 US MARKET ANALYSIS BY FORMULATION |
    8. 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    9. 6.6 US MARKET ANALYSIS BY THERAPEUTIC AREA |
    10. 6.7 CANADA MARKET ANALYSIS BY APPLICATION |
    11. 6.8 CANADA MARKET ANALYSIS BY FORMULATION |
    12. 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    13. 6.10 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY APPLICATION |
    16. 6.13 GERMANY MARKET ANALYSIS BY FORMULATION |
    17. 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
    19. 6.16 UK MARKET ANALYSIS BY APPLICATION |
    20. 6.17 UK MARKET ANALYSIS BY FORMULATION |
    21. 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    22. 6.19 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
    23. 6.20 FRANCE MARKET ANALYSIS BY APPLICATION |
    24. 6.21 FRANCE MARKET ANALYSIS BY FORMULATION |
    25. 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
    27. 6.24 RUSSIA MARKET ANALYSIS BY APPLICATION |
    28. 6.25 RUSSIA MARKET ANALYSIS BY FORMULATION |
    29. 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    31. 6.28 ITALY MARKET ANALYSIS BY APPLICATION |
    32. 6.29 ITALY MARKET ANALYSIS BY FORMULATION |
    33. 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    34. 6.31 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
    35. 6.32 SPAIN MARKET ANALYSIS BY APPLICATION |
    36. 6.33 SPAIN MARKET ANALYSIS BY FORMULATION |
    37. 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY FORMULATION |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY APPLICATION |
    45. 6.42 CHINA MARKET ANALYSIS BY FORMULATION |
    46. 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    47. 6.44 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    48. 6.45 INDIA MARKET ANALYSIS BY APPLICATION |
    49. 6.46 INDIA MARKET ANALYSIS BY FORMULATION |
    50. 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    51. 6.48 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    52. 6.49 JAPAN MARKET ANALYSIS BY APPLICATION |
    53. 6.50 JAPAN MARKET ANALYSIS BY FORMULATION |
    54. 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY FORMULATION |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY FORMULATION |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    64. 6.61 THAILAND MARKET ANALYSIS BY APPLICATION |
    65. 6.62 THAILAND MARKET ANALYSIS BY FORMULATION |
    66. 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
    68. 6.65 INDONESIA MARKET ANALYSIS BY APPLICATION |
    69. 6.66 INDONESIA MARKET ANALYSIS BY FORMULATION |
    70. 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY FORMULATION |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY APPLICATION |
    78. 6.75 BRAZIL MARKET ANALYSIS BY FORMULATION |
    79. 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
    81. 6.78 MEXICO MARKET ANALYSIS BY APPLICATION |
    82. 6.79 MEXICO MARKET ANALYSIS BY FORMULATION |
    83. 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY FORMULATION |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY FORMULATION |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY FORMULATION, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY FORMULATION, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY APPLICATION, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY FORMULATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Healthcare Market Segmentation

Healthcare By Application (USD Billion, 2025-2035)

  • Allergic Rhinitis
  • Asthma
  • Dermatological Disorders
  • Autoimmune Disorders
  • Inflammatory Bowel Disease

Healthcare By Formulation (USD Billion, 2025-2035)

  • Tablets
  • Inhalation
  • Topical
  • Injectable
  • Intranasal

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Inhalation
  • Topical
  • Injectable

Healthcare By Therapeutic Area (USD Billion, 2025-2035)

  • Respiratory Disorders
  • Dermatology
  • Gastroenterology
  • Rheumatology

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions